Ze Jing Pharmaceuticals (688266.SH) has received the approval notice for drug clinical trials.

Zejing Pharmaceuticals (688266.SH) announced that the company has recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The clinical trial for the injection of ZG006 in combination with HS-20093, with or without Atezolizumab, for the treatment of extensive-stage small cell lung cancer has been approved. According to the requirements of relevant laws and regulations for drug registration, after obtaining the "Drug Clinical Trial Approval Notice", clinical trials must be conducted and approved by the National Medical Products Administration before the drug can be marketed. The approval of the clinical trial for the injection of ZG006 in combination with HS-20093, with or without Atezolizumab, for the treatment of extensive-stage small cell lung cancer will not have a significant impact on the company's recent performance.